Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT5B | P51692 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2377556 | 0.83 | F2 (0.38) | STAT5BALDH1A1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL3635463 | 0.83 | STAT5B (0.44) | STAT5BHSD11B1TAS2R14PTGESKCNH2 | |
| SCHEMBL1856320 | 0.82 | STAT5B (0.42) | STAT5BHSD11B1TAS2R14AKT1ALDH1A1 | |
| SCHEMBL28588131 | 0.81 | TAS2R14 (0.55) | STAT5BHSD11B1TAS2R14PTGESKCNH2 | |
| SCHEMBL2375434 | 0.81 | F2 (0.37) | STAT5BALDH1A1SMN1; SMN2NPSR1MAPT | |
| SCHEMBL1857447 | 0.81 | STAT5B (0.43) | STAT5BHSD11B1TAS2R14ALDH1A1LMNA | |
| SCHEMBL3724224 | 0.81 | CA12 (0.43) | STAT5BHSD11B1TAS2R14NPSR1MAPT | |
| SCHEMBL12550326 | 0.81 | STAT5B (0.52) | STAT5BHSD11B1TAS2R14MAPTPTGES | |
| SCHEMBL1862225 | 0.80 | KMT2A (0.43) | EGFRERBB2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1860213 | 0.79 | ATM (0.38) | HSD11B1ALDH1A1LMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | STAT5B 4233/4885HSD11B1 826/4885TAS2R14 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.